CCL18 and chronic obstructive pulmonary disease: In the COPD group, the reducing effect of CCL18 at 50 ng/mL on TNFα correlated positively to age (r2 = 0.333; p = 0.038) and negatively to FEV1/FVC (%) (r2 = 0.328; p = 0.04).